{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:25:40Z","timestamp":1761863140681},"reference-count":0,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[1994,9,1]],"date-time":"1994-09-01T00:00:00Z","timestamp":778377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1994,9]]},"abstract":"<jats:p>A single oral dose of 528 mg of bismuth subsalicylate (30 ml of Pepto-Bismol) had no significant effect on the plasma pharmacokinetics of a single oral dose of 750 mg of ciprofloxacin administered to 12 healthy volunteers (six men and six women). These results suggest that ciprofloxacin bioavailability will not be significantly decreased by single doses of bismuth subsalicylate when the two medications are administered simultaneously.<\/jats:p>","DOI":"10.1128\/aac.38.9.2187","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:05:50Z","timestamp":1340841950000},"page":"2187-2190","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Effect of bismuth subsalicylate on ciprofloxacin bioavailability"],"prefix":"10.1128","volume":"38","author":[{"given":"L","family":"Rambout","sequence":"first","affiliation":[{"name":"Clinical Investigation Unit, Ottawa General Hospital, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Sahai","sequence":"additional","affiliation":[{"name":"Clinical Investigation Unit, Ottawa General Hospital, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Gallicano","sequence":"additional","affiliation":[{"name":"Clinical Investigation Unit, Ottawa General Hospital, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Oliveras","sequence":"additional","affiliation":[{"name":"Clinical Investigation Unit, Ottawa General Hospital, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Garber","sequence":"additional","affiliation":[{"name":"Clinical Investigation Unit, Ottawa General Hospital, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.38.9.2187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.38.9.2187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:40:03Z","timestamp":1645458003000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.38.9.2187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,9]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1994,9]]}},"alternative-id":["10.1128\/AAC.38.9.2187"],"URL":"https:\/\/doi.org\/10.1128\/aac.38.9.2187","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,9]]},"assertion":[{"value":"1994-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}